PF-Atlas › Clinical Trials › NCT00514683
Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis
low dose BIBF1120 once daily · Phase 2
Registry ID
NCT00514683
Phase
Phase 2
Status
Completed
Drug / intervention
low dose BIBF1120 once daily
Sponsor
Boehringer Ingelheim
Start
2007-08
Enrollment
432
Locations
92
About this trial
The general purpose of this trial is to investigate the efficacy and safety of 4 dose strategies of BIBF 1120 treatment for 12 months, compared to placebo in patients with idiopathic pulmonary fibrosis. The primary objective of this study is to demonstrate whether at least one dose strategy is superior to placebo in patients with IPF, in modifying the rate of decline of Forced Vital Capacity (FVC). As a secondary objective, additional parameters will be assessed in order to differentiate between dose strategies on the basis of safety and efficacy
Explore related
Medical disclaimer. This page summarizes public trial data for NCT00514683 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.